TRIUMPH trial programme: difference between revisions
Diff·revision 17 → 18·05:43, 15 Jul 2025
Difference between revision 17 and revision 18 of TRIUMPH trial programme. 5 lines changed; the page grew by 514 bytes.
| Revision 17 — 17:05, 15 Jun 2025 FlowTrialFraser (talk) expand §What phase 3 is designed to address 4,035 bytes ±0 | Revision 18 — 05:43, 15 Jul 2025 SurrogateSunday (talk) add category for the trial programme 4,549 bytes +514 | ||
|---|---|---|---|
| 28 | Cardiovascular outcome evidence would require a dedicated trial of the kind run for [[Semaglutide|semaglutide]] as [[SELECT trial|SELECT]].{{r|lincoff2023}} Weight reduction is an intermediate endpoint and does not substitute for outcome data.{{r|ich_e9}} | 28 | Cardiovascular outcome evidence would require a dedicated trial of the kind run for [[Semaglutide|semaglutide]] as [[SELECT trial|SELECT]].{{r|lincoff2023}} Weight reduction is an intermediate endpoint and does not substitute for outcome data.{{r|ich_e9}} |
| 29 | 29 | ||
| + | 30 | == Status and caution == | |
| + | 31 | Retatrutide is investigational. It is not approved anywhere, its phase 3 results are not fully published, and material sold under its name through research-chemical channels is an unapproved compound with no [[Reference standard|reference standard]] generally available for identity confirmation.{{r|jastreboff2023}} | |
| + | 32 | ||
| + | 33 | The {{tl-update}} tag on this article reflects a programme in progress. Figures quoted here are phase 2 figures and should not be treated as the expected phase 3 result. | |
| + | 34 | ||
| 30 | == References == | 35 | == References == |
| 31 | {{reflist}} | 36 | {{reflist}} |